NCT03949088

Brief Summary

The present study is aimed at comparing different strategies of UF profiling, dialysate sodium individualization and sodium profiling (even combining one with the other) and at evaluating the effectiveness of a new UF profile which has an ascending/descending shape. The goal of the study is to provide better dialysis tolerance and lower rates of intradialytic hypotensive events by the application of this UF profile design in combination with a neutral sodium balance.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 7, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 14, 2019

Completed
18 days until next milestone

Study Start

First participant enrolled

June 1, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2021

Completed
Last Updated

May 16, 2019

Status Verified

May 1, 2019

Enrollment Period

2 years

First QC Date

May 7, 2019

Last Update Submit

May 14, 2019

Conditions

Keywords

Intradialytic hypotension (IDH)Ultrafiltration (UF) profilingSodium (Na) profilingHemodialysis

Outcome Measures

Primary Outcomes (1)

  • Occurrence of intradialytic hypotensive episodes (number of episodes within every HD session and time interval from HD start)

    Hypotensive events and symptoms (headache, cramps, nausea and vomiting) will be recorded and analyzed as both number of occurrences and time of occurrence from the beginning of the HD session. IDH will be defined as follows: * "symptomatic IDH": decrease in SBP ≥ 20 mmHg or in MAP ≥ 10 mmHg associated with symptoms (KDIGO definition) * "asymptomatic IDH": drop in BP (SBP ≥ 20 mmHg or MAP ≥ 10 mmHg) within a 20 minutes interval, regardless of symptoms * for patients whose SBP is \< 100 mmHg at the beginning of treatment, the investigators will consider as IDH any decrease of SBP ≥ 10%

    Within each dialysis session from the time of enrolment to the end of each study phase (9-11 weeks)

Secondary Outcomes (2)

  • Achievement of UF

    Within each dialysis session from the time of enrolment to the end of each study phase (9-11 weeks)

  • Dialysis dose

    Within each dialysis session from the time of enrolment to the end of each study phase (9-11 weeks)

Study Arms (3)

Linear descending UF profile

EXPERIMENTAL

2-step descending Na profile, linear descending UF profile 3 weeks (9 sessions)

Other: UF and Na profiling

Run-in & washout phases

EXPERIMENTAL

constant Na concentration, constant UF rate 3 weeks (6+3 sessions)

Other: UF and Na profiling

Ascending/descending UF profile

EXPERIMENTAL

2-step descending Na profile, ascending/descending UF profile 3 weeks (9 sessions)

Other: UF and Na profiling

Interventions

Modulation of UF and dialysate sodium

Ascending/descending UF profileLinear descending UF profileRun-in & washout phases

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • written informed consent
  • age ≥ 18 years
  • thrice weekly HD regimen for more than 6 months
  • "hypotension-prone patients": ≥ 3 episodes of IDH in the month preceding the run-in phase of the study

You may not qualify if:

  • IDWG \< 1.4% of dry weight (corresponding to \< 1 kg in a 70-kg person)
  • twice weekly HD regimen
  • residual daily urine output \> 300 mL
  • active acute disease or hospitalization in the 8 weeks preceding the run-in phase

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Parma - UO Nefrologia AOU

Parma, Italy

Location

Related Publications (1)

  • Peyronel F, Parenti E, Fenaroli P, Benigno GD, Rossi GM, Maggiore U, Fiaccadori E. Integrated strategies to prevent intradialytic hypotension: research protocol of the DialHypot study, a prospective randomised clinical trial in hypotension-prone haemodialysis patients. BMJ Open. 2020 Jul 8;10(7):e036893. doi: 10.1136/bmjopen-2020-036893.

Central Study Contacts

Enrico Fiaccadori, Prof.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
University Professor

Study Record Dates

First Submitted

May 7, 2019

First Posted

May 14, 2019

Study Start

June 1, 2019

Primary Completion

June 1, 2021

Study Completion

June 1, 2021

Last Updated

May 16, 2019

Record last verified: 2019-05

Data Sharing

IPD Sharing
Will not share

Locations